Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale. SIGNIFICANCE: In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Dubourg, G., Morand, A., Mekhalif, F., Godefroy, R., Corthier, A., Yacouba, A., Diakite, A., Cornu, F., Cresci, M., Brahimi, S., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.513305 · Cited by 66
RetractedRETRACTED ARTICLE: Tobacco-smoking-related prevalence of methanogens in the oral fluid microbiota
Grine, G., Terrer, E., Boualam, M. A., Aboudharam, G., Chaudet, H., Ruimy, R., & Drancourt, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27372-7 · Cited by 57
RetractedThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationUrinary tract infections: epidemiology, mechanisms of infection and treatment options
Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3432 · Cited by 4,213
Cited by
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Zhao, L., Jin, S., Wang, S., Zhang, Z., Wang, X., Chen, Z., Wang, X., Huang, S., Zhang, D., & Wu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01947-5 · Cited by 218
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes
Yang, Y., Chen, X., Pan, J., Ning, H., Zhang, Y., Bo, Y., Ren, X., Li, J., Qin, S., Wang, D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.038 · Cited by 208
T follicular helper cells in cancer
Gutiérrez-Melo, N., & Baumjohann, D. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.12.007 · Cited by 209
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citationGut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Self-citationCD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 185
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 136
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationLiu, W., You, W., Lan, Z., Ren, Y., Gao, S., Li, S., Chen, W., Huang, C., Zeng, Y., Xiao, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101448 · Cited by 114
Yang, Z., Tian, H., Chen, X., Li, B., Bai, G., Cai, Q., Xu, J., Guo, W., Wang, S., Peng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52977-0 · Cited by 114
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Self-citationBodywide ecological interventions on cancer
Kroemer, G., McQuade, J. L., Mérad, M., André, F., & Zitvogel, L. (2023) · Nature Medicine · doi:10.1038/s41591-022-02193-4 · Cited by 57
Self-citationCathomas, R. L., Rothschild, S. I., Hayoz, S., Bubendorf, L., Özdemir, B. C., Kiss, B. M., Erdmann, A. A., Aeppli, S., Mach, N., Strebel, R. T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00363 · Cited by 56
Elkrief, A., Montesion, M., Sivakumar, S., Hale, C. R., Bowman, A. S., Bektaş, A. B., Bradić, M., Kang, W., Chan, E., Gogia, P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01488 · Cited by 46
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
Flippot, R., Teixeira, M., Rey-Cárdenas, M., Carril-Ajuria, L., Rainho, L., Naoun, N., Jouniaux, J.-M., Boselli, L., Naigeon, M., Danlos, F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008636 · Cited by 52
Self-citationMature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy
Bao, X., Lin, X., Xie, M., Yao, J., Song, J., Ma, X., Zhang, X., Zhang, Y., Liu, Y., Han, W., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1413067 · Cited by 48
T follicular helper cells in cancer, tertiary lymphoid structures, and beyond
Cui, C., Craft, J. E., & Joshi, N. S. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101797 · Cited by 48
Non-mutational neoantigens in disease
Stern, L. J., Clement, C. C., Galluzzi, L., & Santambrogio, L. (2024) · Nature Immunology · doi:10.1038/s41590-023-01664-1 · Cited by 46
Long, F., Wang, W., Li, S., Wang, B., Hu, X., Wang, J., Xu, Y., Liu, M., Zhou, J., Si, H., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04151-1 · Cited by 39
Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
Terrisse, S. A., Zitvogel, L., & Kroemer, G. (2022) · Microbial Cell · doi:10.15698/mic2022.12.787 · Cited by 38
Self-citationTertiary lymphoid structures in cancer: immune mechanisms and clinical implications
Wang, S., Wang, H., Li, C., Liu, B., He, S., & Tu, C. (2024) · MedComm · doi:10.1002/mco2.489 · Cited by 40
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
Self-citationGu, X., Li, D., Wu, P., Zhang, C., Cui, X., Shang, D., Ma, R., Liu, J., Sun, N., & He, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217278 · Cited by 27
Gut Microbiota–Related Biomarkers in Immuno-Oncology
Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061124-102218 · Cited by 22
Self-citationCui, M., Zhou, M., Zhou, L., Zhou, G., & Liu, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189312 · Cited by 24
Vion, R., Dugage, M. R., Flippot, R., Ouali, K., Rouanne, M., Clatot, F., Sellars, M., Champiat, S., Chaput, N., Massard, C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115572 · Cited by 23
Self-citationGut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
Could the tumor-associated microbiota be the new multi-faceted player in the tumor microenvironment?
Goubet, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1185163 · Cited by 19
Self-citationWu, C., Wei, X., Huang, Z., Zheng, Z., Zhang, W., Chen, J., Hong, H., & Li, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05446-7 · Cited by 26
Yang, R., Wang, S., Li, Z., Yin, C., Huang, W., & Huang, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217793 · Cited by 24
CXCL10 could be a prognostic and immunological biomarker in bladder cancer
Yin, T., Mou, S., Zhang, H., Dong, Y., Yan, B., Huang, W., Liu, Y., & Mei, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-00982-6 · Cited by 15
The Sunrise of Tertiary Lymphoid Structures in Cancer
Rochefort, J., Marodon, G., Teillaud, J., & Dieu‐Nosjean, M. (2025) · Immunological Reviews · doi:10.1111/imr.70046 · Cited by 16
Chung, R., McKiernan, J., Arpaia, N., Marabelle, A., & Rouanne, M. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.037 · Cited by 15
Self-citationB cells are major players in cancer immunity
Bouloudani, T., Pupier, G., Sautès‐Fridman, C., & Fridman, W. H. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107064 · Cited by 12
From mucosal infection to successful cancer immunotherapy
Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00784-5 · Cited by 11
Self-citationKnowledge-map analysis of bladder cancer immunotherapy
Lv, Z., Hou, J., Wang, Y., Wang, X., Wang, Y., & Wang, K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2267301 · Cited by 14
Riaz, N., Alban, T. J., Haddad, R. I., Saul, M. E., Makarov, V., Zhu, Y., Cohen, E. E. W., Ferris, R. L., Chang, P. M., Lin, J.-C., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01068-0 · Cited by 18
Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy
Hou, J., Yang, X., Xie, S., Zhu, B., & Zha, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371559 · Cited by 15
Kawashima, A., Ishizuya, Y., Yamamoto, Y., Kato, T., Hatano, K., & Nonomura, N. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02526-y · Cited by 10
Jaeghere, E. A. D., Hamerlinck, H., Tuyaerts, S., Lippens, L., Nuffel, A. M. T. V., Baiden-Amissah, R. E. M., Vuylsteke, P., Henry, S., Trinh, X. B., van Dam, P. A., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.10.020 · Cited by 13
Blanc, J., Carnot, A., Barthélémy, P., Casert, V., Sautois, B. R., den Brande, J. V., Vanhaudenarde, V., Staudacher, L., Seront, E., Debien, V., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012045 · Cited by 12
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy
Almonte, A. A., & Zitvogel, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011540 · Cited by 9
Self-citationGalsky, M. D., Bajorin, D. F., Tomita, Y., Ye, D., Agerbæk, M., Enting, D., Peer, A., Milowsky, M. I., Kobayashi, K., Grimm, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03802-8 · Cited by 12
Mechanisms by Which the Intratumoral Microbiome May Potentiate Immunotherapy Response
Figueroa, D. N., & Colbert, L. E. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00908 · Cited by 7
Tertiary Lymphoid Structures in Microorganism-Related Cancer
Deng, S., Yang, X., He, L., Hou, Y., & Meng, H. (2024) · Cancers · doi:10.3390/cancers16203464 · Cited by 8
Tertiary Lymphoid Structures: Allies of Cancer Immunotherapy
Li, X., Zhang, X., Cao, Z., Guan, J., Qiu, F., Zhang, Q., & Kang, N. (2025) · Immunology · doi:10.1111/imm.70020 · Cited by 10
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling
Suissa, D., Fidelle, M., Reich, E., Pham, T.-N., Thomas, S., Björk, J. R., Liu, P., Zhao, L., Kitaoka, K., Piard, E., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04481-9 · Cited by 10
Self-citationSilva, C. A. C., Almonte, A. A., & Zitvogel, L. (2025) · Biomolecules · doi:10.3390/biom15040504 · Cited by 6
Self-citationThe interplay between the immune response and neoadjuvant therapy in breast cancer
Thomas, N., Foukakis, T., & Willard-Gallo, K. E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1469982 · Cited by 5
Zhang, Y., Li, H., Lv, S., Meng, W., Guo, J., Lu, Y., Peng, L., Wu, C., Wen, Y., & Peng, X. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02735-1 · Cited by 9
Zhao, K., Xu, G., Jin, J., Peng, C., Chen, J., Li, Y., Wang, W., & Pan, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02581-5 · Cited by 5
Szállási, Z., Prósz, A. G., Sztupinszki, Z. M., & Moldvay, J. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2324493 · Cited by 5
Mansourabadi, Z., Ariafar, A., Chenari, N., Hakimelahi, H., Vahidi, Y., & Faghih, Z. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-70675-1 · Cited by 6
Translational Advances in Urothelial Carcinoma: From Bench to Bedside
Iwasawa, T., Tsujino, T., Tsukahara, S., Fukushima, H., Ito, D., Tomiyama, E., & Urabe, F. (2026) · International Journal of Urology · doi:10.1111/iju.70341 · Cited by 4
Liu, G., Jin, K., Liu, Z., Su, X., Xu, Z., Li, B., Xu, J., Liu, H., Chang, Y., Zhu, Y., et al. (2024) · Cancer Science · doi:10.1111/cas.16119 · Cited by 3
Integrating novel immunotherapeutic approaches in organ‐preserving therapies for bladder cancer
Michaud, E., Mansure, J. J., & Kassouf, W. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16300 · Cited by 4
Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update
Giannakodimos, I., Ziogou, A., Giannakodimos, A., Tzelepis, K., Kratiras, Z., Fragkiadis, E., Zachos, I., Tzortzis, V., Chrisofos, M., & Charalampakis, N. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2501929 · Cited by 5
Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis
Kepp, O., Zitvogel, L., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2212547 · Cited by 3
Self-citationThe lethal symbiont: exploring the pathophysiology of cancer
Nolan, E., Li, L., Giampazolias, E., Ombrato, L., & Malanchi, I. (2026) · Physiological Reviews · doi:10.1152/physrev.00019.2025 · Cited by 2
Conejo-Garcia, J. R., Lopez-Bailon, L. U., & Anadon, C. M. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae179 · Cited by 3
Hassouneh, Z., Kim, M. E., Bowman, N., Rao, M. K., Zhang, N., Huang, G., Svatek, R. S., & Mukherjee, N. Z. (2024) · Cancers · doi:10.3390/cancers16193303 · Cited by 7
Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapyPreprint
Rouanne, M., Chen, N., Mariuzza, D. L., Li, F., Santos, K. D. L., Savage, T. M., Vincent, R. L., Mendelsohn, C. L., Danino, T., & Arpaia, N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.24.620122 · Cited by 2
Self-citationXu, Q. H., Shi, L., Dizon, B. L. P., Beam, R. J., Mudd, P. A., Schwartzberg, P. L., & Manthiram, K. (2025) · Journal of Visualized Experiments · doi:10.3791/67188 · Cited by 2
Pan, Z., Zhang, F., Zhang, C., Li, X., Ma, Y., Yang, Y., & Tian, X. (2026) · iScience · doi:10.1016/j.isci.2026.116029 · Cited by 1
Xu, Y., & Li, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849305 · Cited by 1
Wang, G., Cui, Z., Jiang, X., Sun, Y., Liu, Y., Li, X., Li, W., Sun, R., Liu, X., Yu, N., et al. (2026) · Science Advances · doi:10.1126/sciadv.aee2483 · Cited by 1
Bacteria displaying cytokines heat up the tumor microenvironment
Fidelle, M., & Zitvogel, L. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02429-3 · Cited by 1
Self-citationGlobal research prospects and trends in TFH cells and tumors: a bibliometric analysis
Hao, L., Hu, J., Zhu, J., Li, R., Zhao, Y. F., Zhao, Y., He, G., Song, T., Lu, C., Zheng, W.-P., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1443890 · Cited by 3
Lee, H. W., & Sung, H. H. (2025) · Journal of Urologic Oncology · doi:10.22465/juo.255000300015 · Cited by 1
Impact du microbiote intestinal dans les cancers colorectaux
Fidelle, M., Chen, J., Roberti, M. P., Kroemer, G., & Zitvogel, L. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.09.009
Self-citationCXCL10 could be a prognostic and immunological biomarker in bladder cancerPreprint
殷, 涛., mou, S., Zhang, H., Dong, Y., Yan, B., Huang, W., Liu, Y., & Mei, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3921289/v1
Mansourabadi, Z., Ariafar, A., Chenari, N., Hakimelahi, H., Vahidi, Y., & Faghih, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-4226174/v1
Long, F., Wang, W., Li, S., Wang, B., Hu, X., Wang, J., Xu, Y., Liu, M., Zhou, J., Si, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26586597
Wu, C., Wei, X., Huang, Z., Zheng, Z., Zhang, W., Chen, J., Hong, H., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.26744507
Long, F., Wang, W., Li, S., Wang, B., Hu, X., Wang, J., Xu, Y., Liu, M., Zhou, J., Si, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26586603
Long, F., Wang, W., Li, S., Wang, B., Hu, X., Wang, J., Xu, Y., Liu, M., Zhou, J., Si, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26586600
Long, F., Wang, W., Li, S., Wang, B., Hu, X., Wang, J., Xu, Y., Liu, M., Zhou, J., Si, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26586606
Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer
Váradi, M., Magyar, B., Széles, Á. D., Korda, S., Németh, B., Simon, B. F., Reis, H., Oláh, C., Horváth, O. N., Dér, B., et al. (2026) · Pathology & Oncology Research · doi:10.3389/pore.2026.1612333
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Li, Y. L., Wei, W., Liu, C., 陆浩源, Chen, R., Wu, S., Lin, Y., Xie, H., Ban, C., Yi, X., et al. (2026) · Journal of International Medical Research · doi:10.1177/03000605261441388
Barnes, R., Cummings, K. L., Lanfranca, M. P., Rodriguez, A. B., Stasiak, K., Ludewig, B., Dolatshahi, S., & Engelhard, V. H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857037 · Cited by 1
Tertiary Lymphoid Structures and CXCL13 as Targets in Intracranial Aneurysm
Zheng, Z., Lu, Z., Han, Z., He, Q., Wang, N., Zhang, X., Ge, P., Li, J., Zhang, B., Ma, X., et al. (2026) · Circulation Research · doi:10.1161/circresaha.125.328094
Rouanne, M., Chen, N., Mariuzza, D. L., Yang, Z., Li, F., Santos, K. D. L., Savage, T. M., Vincent, R. L., Mendelsohn, C. L., Danino, T., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adv7600 · Cited by 3
Self-citationWei, X., Pei, X., & Yu, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1853633
Advances in Spatial Heterogeneity and Cellular Localization Specificity of Intratumoral Bacteria
Ren, M., Jia, J., Li, T., Li, Y., Shen, N., Shi, Y., Wang, Z., Fan, H., Sun, G., Xiong, G., et al. (2026) · Cancer Science · doi:10.1111/cas.70536
CXCR5 regulates CD8+/GZMB+ T cell infiltration and apoptotic signaling in breast cancer
Feng, W., Yan, J., Gong, X., Hu, J.-D., Jin, M.-L., Ma, C.-H., & Li, F.-G. (2026) · iScience · doi:10.1016/j.isci.2026.117874
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications
Porcari, S., Bolte, L. A., Björk, J. R., Elkrief, A., Derosa, L., Ferrari, M., Pezzullo, A. M., Severino, A., Fusco, W. G., Messaoudene, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.012
Self-citation
Metadata
- Authors
- Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., Pignot, G., Gravis, G., Helissey, C., Campedel, L., Roupret, M., Xylinas, E., Ouzaid, I., Dubuisson, A., Mazzenga, M., Flament, C., Ly, P., Marty, V., Signolle, N., Sauvat, A., Sbarrato, T., Filahi, M., Davin, C., Haddad, G., Bou Khalil, J., Bleriot, C., Danlos, F.-X., Dunsmore, G., Mulder, K., Silvin, A., Raoult, T., Archambaud, B., Belhechmi, S., Gomperts Boneca, I., Cayet, N., Moya-Nilges, M., Mallet, A., Daillere, R., Rouleau, E., Radulescu, C., Allory, Y., Fieschi, J., Rouanne, M., Ginhoux, F., Le Teuff, G., Derosa, L., Marabelle, A., Van Dorp, J., Van Dijk, N., Van Der Heijden, M. S., Besse, B., Andre, F., Merad, M., Kroemer, G., Scoazec, J.-Y., Zitvogel, L., & Loriot, Y.
- Affiliations
- Inserm (FR)
- 1Gustave Roussy, Villejuif, France.
- 6Urology Department, University Hospital of Bicêtre-Paris Sud-Saclay University, Le Kremlin Bicêtre, Paris, France.
- Université Paris Cité (FR)
- Institut Paoli-Calmettes (FR)
- 10Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.
- 11Military Hospital Begin, Saint-Mandé, France.
- Sorbonne Université (FR)
- 13GRC 5 Predictive Onco-Uro, Sorbonne University, Department of Urology, AP-HP, Pitie-Salpetriere Hospital, Paris, France.
- Hôpital Bichat-Claude-Bernard (FR)
- 14Department of Urology, Bichat-Claude Bernard Hospital, Paris University, Paris France.
- 18Veracyte, Marseille, France.
- Institut de Recherche pour le Développement (FR)
- 19Aix-Marseille University, IRD, APHM, MEPHI, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- 22Institut Pasteur, Université de Paris, CNRS UMR2001, INSERM U1306, Unité de Biologie et Génétique de la paroi bactérienne, Paris, France.
- Institut Pasteur (FR)
- 23Core Facility Ultrastructural BioImaging Core Facility, Institut Pasteur, Paris France.
- 24EverImmune, Gustave Roussy, Villejuif, France.
- 25Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Agency for Science, Technology and Research (SG)
- 31Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 32Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 35The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Goubet, Anne-Gaëlle
- Lordello, Leonardo
- Alves Costa Silva, Carolina
- Peguillet, Isabelle
- Gazzano, Marianne
- Mbogning-Fonkou, Maxime Descartes
- Thelemaque, Cassandra
- Lebacle, Cédric
- Thibault, Constance
- Audenet, François
- Pignot, Géraldine
- Gravis, Gwenaelle
- Helissey, Carole
- Campedel, Luca
- Roupret, Morgan
- Xylinas, Evanguelos
- Ouzaid, Idir
- Dubuisson, Agathe
- Mazzenga, Marine
- Flament, Caroline
- Ly, Pierre
- Marty, Virginie
- Signolle, Nicolas
- Sauvat, Allan
- Sbarrato, Thomas
- Filahi, Mounia
- Davin, Caroline
- Haddad, Gabriel
- Bou Khalil, Jacques
- Bleriot, Camille
- Danlos, François-Xavier
- Dunsmore, Garett
- Mulder, Kevin
- Silvin, Aymeric
- Raoult, Thibault
- Archambaud, Baptiste
- Belhechmi, Shaima
- Gomperts Boneca, Ivo
- Cayet, Nadège
- Moya-Nilges, Maryse
- Mallet, Adeline
- Daillere, Romain
- Rouleau, Etienne
- Radulescu, Camelia
- Allory, Yves
- Fieschi, Jacques
- Rouanne, Mathieu
- Ginhoux, Florent
- Le Teuff, Gwénaël
- Derosa, Lisa
- Marabelle, Aurélien
- Van Dorp, Jeroen
- Van Dijk, Nick
- Van Der Heijden, Michiel S.
- Besse, Benjamin
- Andre, Fabrice
- Merad, Miriam
- Kroemer, Guido
- Scoazec, Jean-Yves
- Zitvogel, Laurence
- Loriot, Yohann
- Venue
- Cancer Discovery
- Published
- 2022-08-05
- Volume
- 12
- Issue
- 10
- Pages
- 2280-2307
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4289936629
- Cited by
- 86
- References
- 85
- Citations by year
- 2026: 18 · 2025: 18 · 2024: 33 · 2023: 16 · 2022: 1
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Funders
- Fondation pour la Recherche Médicale (FDM201806006036)
- RHU5 (ANR-21-RHUS-0017)
- RHU Torino Lumiere (ANR-16-RHUS-0008)
- ANR (19-CE15-0029-01)
- EU-H2020 (825410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- muscle-invasive bladder cancer, neoadjuvant pembrolizumab, anti-PD-1 therapy, T follicular helper cells, CXCL13, Escherichia coli, tumor-infiltrating immune cells, tertiary lymphoid structures, PD-L1, treatment response biomarkers, progression-free survival
- MeSH terms
- Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Escherichia coli, T-Lymphocytes, Helper-Inducer, Humans, Immunoglobulin G, Muscles, Treatment Outcome, Neoadjuvant Therapy, Chemokine CXCL13, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.